Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)
Updated: Jun 22, 2022
Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)
The purpose of this study is to assess the clinical effectiveness of all approved multiple myeloma (MM) therapies in the newly-diagnosed (NDMM) and the relapsed/refractory MM (RRMM) settings in real-world clinical practice.
Sponsor
Bristol-Myers Squibb
Multiple Locations
International Study
ClinicalTrials.gov Identifier: NCT01838512
Official Title: Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)
First Posted : April 24, 2013
Click here to see details on ClinicalTrials.gov
Locations
United States, Alabama
United States, Arizona
United States, California
United States, District of Columbia
United States, Florida
United States, Georgia
United States, Illinois
United States, Indiana
United States, Iowa
United States, Kentucky
United States, Louisiana
United States, Minnesota
United States, Mississippi
United States, Missouri
United States, Montana
United States, Nebraska
United States, New Jersey
United States, New York
United States, North Carolina
United States, Ohio
United States, Oklahoma
United States, Oregon
United States, Pennsylvania
United States, South Carolina
United States, Tennessee
United States, Texas
United States, Washington
Canada, Ontario
Europe
United Kingdom
France
Germany
Italy